Last updated: 14 days ago
AstraZeneca's Enhertu: Breakthrough in HER2-Positive Breast Cancer Treatment
Discover the pivotal findings from AstraZeneca's DESTINY-Breast09 trial, showcasing Enhertu's potential in HER2-positive metastatic breast cancer and its impact on patient care.